Dopamine receptors as cancer biomarker

HKBU develops iridium probes that could lead to novel early-detection technology for cancer

Register for free to listen to this article
Listen with Speechify
HONG KONG—A team led by Dr. Edmond Dik-Lung Ma, an associate professor of the Department of Chemistry of Hong Kong Baptist University (HKBU) has developed the world’s first iridium(III)-based probes for imaging dopamine receptors in living cells. The discovery has the potential to vastly enhance the understanding of dopamine receptors in carcinogenesis, and HKBU believes the findings might potentially be developed into a novel early cancer detection technology. The study was published in Chemical Science, the flagship journal of the Royal Society of Chemistry.
Dopamine is an important neurotransmitter in the central nervous system of the human body and plays important roles in motivation, cognition and motor control. While dopamine receptors have long been implicated in neurodegenerative diseases such as Parkinson’s disease, recent evidence has linked dopamine receptors also with various cancers, including lung, breast and colon cancers. Traditional detection methods for dopamine receptors include the enzyme-linked immunosorbent assay, more commonly known as the ELISA). However, such methods suffer from high cost, incompatibility with living systems and are not suitable for the real-time study of the biological role of dopamine receptors.
The metal-based probes developed by the team are reportedly able to selectively bind to dopamine receptors on lung cancer cells, “lighting up” the cells and making them visible to the naked eye. The probes enable the monitoring and tracking of dopamine receptors in living cells in real-time and in a non-invasive fashion. Moreover, the experiment results demonstrated that the imaging color intensity was correlated with the expression levels of dopamine receptors on cancer cells. These probes could therefore both help to elucidate the role of dopamine receptors in the pathogenesis of cancers and offer a potential diagnostic tool for the early screening of cancers. Importantly, the metal-based probes avoid the problems of poor photostability and photobleaching that limit conventional fluorescent imaging dyes.
“Early detection is crucial for improving the survival rate of hard-to-treat cancers such as lung cancer, which is associated with dopamine receptor expression,” said Ma. “For instance, data from the American Cancer Society shows that patients with early-stage non-small cell lung cancer have a five-year survival rate of about 92 percent, but this drops to only about 36 percent when the cancer has progressed to an advanced stage. We therefore believe that these dopamine receptor probes show great promise for the development of molecular diagnostic tools for the early detection of cancer.”
Ma added that because the probes could successfully track the internalization process of dopamine receptors in cells, they also represent powerful tools for studying the role of dopamine receptors in the pathogenesis of cancer.

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue